应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
IBD Inspire Corporate Bond ETF
休市中 10-02 16:00:00 EDT
23.02
+0.01
+0.04%
盘后
23.00
-0.02
-0.09%
19:30 EDT
最高
23.16
最低
22.52
成交量
6.04万
今开
23.05
昨收
23.01
日振幅
2.78%
总市值
5.02亿
流通市值
5.02亿
总股本
2,180万
成交额
138.92万
换手率
0.28%
流通股本
2,180万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Organovo Holdings, Inc.盘中异动 下午盘快速下跌6.37%报0.422美元
市场透视 · 2025-03-11
Organovo Holdings, Inc.盘中异动 下午盘快速下跌6.37%报0.422美元
Organovo Holdings, Inc.盘中异动 快速下挫6.10%
市场透视 · 2025-03-05
Organovo Holdings, Inc.盘中异动 快速下挫6.10%
艾伯维杀入减重赛道 寻找下一个“药王”？
新京报 · 2025-03-04
艾伯维杀入减重赛道 寻找下一个“药王”？
Organovo Holdings, Inc.股价重挫10.77% 市值跌109.04万美元
市场透视 · 2025-03-03
Organovo Holdings, Inc.股价重挫10.77% 市值跌109.04万美元
Organovo Holdings, Inc.盘中异动 早盘大幅跳水5.55%
市场透视 · 2025-02-28
Organovo Holdings, Inc.盘中异动 早盘大幅跳水5.55%
Organovo Holdings, Inc.盘中异动 早盘股价大跌8.09%
市场透视 · 2025-02-27
Organovo Holdings, Inc.盘中异动 早盘股价大跌8.09%
Organovo Holdings, Inc.股价拉升11.82% 市值涨292.98万美元
市场透视 · 2025-02-26
Organovo Holdings, Inc.股价拉升11.82% 市值涨292.98万美元
Organovo Holdings, Inc.股价上涨238.75% 市值涨5209.05万美元
市场透视 · 2025-02-25
Organovo Holdings, Inc.股价上涨238.75% 市值涨5209.05万美元
Organovo Holdings, Inc.盘中异动 股价大跌5.15%报0.350美元
市场透视 · 2025-02-25
Organovo Holdings, Inc.盘中异动 股价大跌5.15%报0.350美元
Organovo Holdings, Inc.盘中异动 股价大跌5.51%
市场透视 · 2025-02-20
Organovo Holdings, Inc.盘中异动 股价大跌5.51%
Organovo Holdings, Inc.盘中异动 股价大跌5.96%报0.363美元
市场透视 · 2025-02-18
Organovo Holdings, Inc.盘中异动 股价大跌5.96%报0.363美元
Organovo Holdings, Inc.盘中异动 股价大涨5.82%报0.400美元
市场透视 · 2025-02-15
Organovo Holdings, Inc.盘中异动 股价大涨5.82%报0.400美元
Organovo Holdings, Inc.盘中异动 早盘快速拉升5.02%
市场透视 · 2025-02-13
Organovo Holdings, Inc.盘中异动 早盘快速拉升5.02%
MNC年报扫描｜巨头“厮杀” 国产“逐鹿”：自免领域5大单品狂揽近530亿美元
21世纪经济报道 · 2025-02-07
MNC年报扫描｜巨头“厮杀” 国产“逐鹿”：自免领域5大单品狂揽近530亿美元
【礼来(LLY.US)IL-23p19单抗mirikizumab获批克罗恩病新适应症】1月15日，礼来(LLY.US)宣布，其IL-23p19单抗mirikizumab(Omvoh)已获FDA批准第2项适应症，用于治疗成人中度至重度活动性克罗恩病。Mirikizumab继2023年10月被批准为治疗中度至重度活动性成人溃疡性结肠炎(UC)的同类首创疗法之后，现在又被批准用于治疗两种类型的炎症性肠病(IBD)。
金融界 · 2025-01-16
【礼来(LLY.US)IL-23p19单抗mirikizumab获批克罗恩病新适应症】1月15日，礼来(LLY.US)宣布，其IL-23p19单抗mirikizumab(Omvoh)已获FDA批准第2项适应症，用于治疗成人中度至重度活动性克罗恩病。Mirikizumab继2023年10月被批准为治疗中度至重度活动性成人溃疡性结肠炎(UC)的同类首创疗法之后，现在又被批准用于治疗两种类型的炎症性肠病(IBD)。
MNC年度涨幅榜，意外的榜一
蓝鲸财经 · 2025-01-10
MNC年度涨幅榜，意外的榜一
医药行业周报：艾伯维将以2亿美元收购NIMBLE 布局自免领域
太平洋证券股份... · 2024-12-17
医药行业周报：艾伯维将以2亿美元收购NIMBLE 布局自免领域
武田掀起新一轮裁员潮！专利悬崖、管线调整之后，整合能否找到出路？
医药经济报 · 2024-10-27
武田掀起新一轮裁员潮！专利悬崖、管线调整之后，整合能否找到出路？
信达生物宣布匹康奇拜单抗（IL-23p19抗体）治疗溃疡性结肠炎的II期临床研究达成主要终点
美通社 · 2024-10-17
信达生物宣布匹康奇拜单抗（IL-23p19抗体）治疗溃疡性结肠炎的II期临床研究达成主要终点
加载更多
公司概况
公司名称：
Inspire Corporate Bond ETF
所属市场：
ARCA
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":23.02,"timestamp":1790971200000,"preClose":23.01,"halted":0,"volume":60407,"hourTrading":{"tag":"盘后","latestPrice":23,"preClose":23.02,"latestTime":"19:30 EDT","volume":901,"amount":20723.26,"timestamp":1790983804776,"change":-0.02,"changeRate":-0.000869,"amplitude":0},"delay":0,"changeRate":0.0004345936549325515,"floatShares":21801743,"shares":21801743,"eps":0,"marketStatus":"休市中","change":0.01,"latestTime":"10-02 16:00:00 EDT","open":23.05,"high":23.16,"low":22.52,"amount":1389231.970648,"amplitude":0.027814,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":23.01,"sharesOutstanding":19800000,"nav":22.98,"aum":500979198.03,"dividendRate":0.043775,"bidAskSpread":0.006615,"postHourTrading":{"tag":"盘后","latestPrice":23,"preClose":23.02,"latestTime":"19:30 EDT","volume":901,"amount":20723.26,"timestamp":1790983804776,"change":-0.02,"changeRate":-0.000869,"amplitude":0},"volumeRatio":0.7823241127128201},"requestUrl":"/m/hq/s/IBD/","defaultTab":"news","newsList":[{"id":"2518420501","title":"Organovo Holdings, Inc.盘中异动 下午盘快速下跌6.37%报0.422美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518420501","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518420501?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:05","pubTimestamp":1741626341,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时05分，Organovo Holdings, Inc.股票出现异动，股价大幅下挫6.37%。截至发稿，该股报0.422美元/股，成交量27.3231万股，换手率1.57%，振幅8.70%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311010542abf34a26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311010542abf34a26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONVO","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517908945","title":"Organovo Holdings, Inc.盘中异动 快速下挫6.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517908945","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517908945?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:43","pubTimestamp":1741185821,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时43分，Organovo Holdings, Inc.股票出现波动，股价急速下挫6.10%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224341963adf65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224341963adf65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","IBD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516260096","title":"艾伯维杀入减重赛道 寻找下一个“药王”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2516260096","media":"新京报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516260096?lang=zh_cn&edition=full","pubTime":"2025-03-04 18:00","pubTimestamp":1741082458,"startTime":"0","endTime":"0","summary":"艾伯维还是杀入了减重赛道。美国时间3月3日，艾伯维宣布与Gubra公司达成许可协议，共同开发用于治疗肥胖症的潜在同类最佳长效胰淀素类似物，交易总额最高可达22亿美元。当前减重赛道火热，2024年两款全球畅销减重药物更是合计卖出了457.42亿美元。自旗下修美乐因专利到期等因素销售开始下滑后，艾伯维业绩受到影响，近年来也在频频对外合作，提振业绩。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503043336126264.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043336126264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516634704","title":"Organovo Holdings, Inc.股价重挫10.77% 市值跌109.04万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516634704?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:30","pubTimestamp":1741012250,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时30分，Organovo Holdings, Inc.股票出现异动，股价大幅下跌10.77%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032230509637ab9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032230509637ab9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","ONVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2514583373","title":"Organovo Holdings, Inc.盘中异动 早盘大幅跳水5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514583373","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514583373?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:51","pubTimestamp":1740754266,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时51分，Organovo Holdings, Inc.股票出现异动，股价急速下挫5.55%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.22%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822510696341eaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822510696341eaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IBD","ONVO"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2514385603","title":"Organovo Holdings, Inc.盘中异动 早盘股价大跌8.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385603","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514385603?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:37","pubTimestamp":1740667027,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时37分，Organovo Holdings, Inc.股票出现波动，股价急速下挫8.09%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.85%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272237079632b21c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272237079632b21c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","BK4139","IBD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2514518578","title":"Organovo Holdings, Inc.股价拉升11.82% 市值涨292.98万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514518578","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514518578?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:32","pubTimestamp":1740580349,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时32分，Organovo Holdings, Inc.股票出现异动，股价快速拉升11.82%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Enveric Biosciences, Inc.、Nutriband Inc C/Wts 、Channel Therapeutics Corporation涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为2837.58%、119.45%、90.45%，振幅较大的相关个股有Enveric Biosciences, Inc.、Channel Therapeutics Corporation、Cns Pharmaceuticals, Inc.，振幅分别为35.59%、16.86%、14.35%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223230a254f6af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223230a254f6af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","BK4139","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514090481","title":"Organovo Holdings, Inc.股价上涨238.75% 市值涨5209.05万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090481","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514090481?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:31","pubTimestamp":1740493865,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时31分，Organovo Holdings, Inc.股票出现异动，股价急速上涨238.75%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Organovo Holdings, Inc.、Moleculin Biotech, Inc.、Silexion Therapeutics Corp涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为746.23%、508.78%、459.72%，振幅较大的相关个股有Organovo Holdings, Inc.、Igm Biosciences, Inc.、Bicara Therapeutics Inc.，振幅分别为8.13%、7.46%、5.62%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223105abdc7da6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223105abdc7da6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IBD","ONVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514670511","title":"Organovo Holdings, Inc.盘中异动 股价大跌5.15%报0.350美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514670511","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514670511?lang=zh_cn&edition=full","pubTime":"2025-02-25 04:35","pubTimestamp":1740429350,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时35分，Organovo Holdings, Inc.股票出现波动，股价快速跳水5.15%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.14%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225043550962ee007&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225043550962ee007&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","ONVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512480684","title":"Organovo Holdings, Inc.盘中异动 股价大跌5.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512480684","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512480684?lang=zh_cn&edition=full","pubTime":"2025-02-20 01:31","pubTimestamp":1739986261,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日01时31分，Organovo Holdings, Inc.股票出现波动，股价快速下跌5.51%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013101988b4e5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013101988b4e5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","ONVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512612521","title":"Organovo Holdings, Inc.盘中异动 股价大跌5.96%报0.363美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512612521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512612521?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:25","pubTimestamp":1739892328,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时25分，Organovo Holdings, Inc.股票出现波动，股价大幅下挫5.96%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218232528a24ab8fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218232528a24ab8fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","ONVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511137666","title":"Organovo Holdings, Inc.盘中异动 股价大涨5.82%报0.400美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511137666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511137666?lang=zh_cn&edition=full","pubTime":"2025-02-15 02:04","pubTimestamp":1739556283,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日02时04分，Organovo Holdings, Inc.股票出现波动，股价大幅上涨5.82%。截至发稿，该股报0.400美元/股，成交量8.5386万股，换手率0.56%，振幅6.08%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.50%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150204439885bb0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150204439885bb0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","ONVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511243345","title":"Organovo Holdings, Inc.盘中异动 早盘快速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511243345","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511243345?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:43","pubTimestamp":1739461383,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时43分，Organovo Holdings, Inc.股票出现波动，股价急速上涨5.02%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.50%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213234303abcdc059&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213234303abcdc059&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","ONVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509791469","title":"MNC年报扫描｜巨头“厮杀” 国产“逐鹿”：自免领域5大单品狂揽近530亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509791469","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509791469?lang=zh_cn&edition=full","pubTime":"2025-02-07 16:39","pubTimestamp":1738917574,"startTime":"0","endTime":"0","summary":"随着跨国药企（MNC）陆续披露2024年业绩，21世纪经济报道记者初步统计发现，自免领域的营收排名中，赛诺菲的度普利尤单抗、艾伯维的利生奇珠单抗和阿达木单抗、强生的乌司奴单抗、罗氏的奥瑞利珠单抗位居前5，年内销售额合计529.31亿美元。在这5款产品中，度普利尤单抗作为全球首个获批上市的IL-4Rα靶向单抗，凭借不断拓宽的适应症，成为全球“自免新王”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502073313516026.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502073313516026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4116","IBD","CD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503916699","title":"【礼来(LLY.US)IL-23p19单抗mirikizumab获批克罗恩病新适应症】1月15日，礼来(LLY.US)宣布，其IL-23p19单抗mirikizumab(Omvoh)已获FDA批准第2项适应症，用于治疗成人中度至重度活动性克罗恩病。Mirikizumab继2023年10月被批准为治疗中度至重度活动性成人溃疡性结肠炎(UC)的同类首创疗法之后，现在又被批准用于治疗两种类型的炎症性肠病(IBD)。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503916699","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503916699?lang=zh_cn&edition=full","pubTime":"2025-01-16 21:15","pubTimestamp":1737033339,"startTime":"0","endTime":"0","summary":"1月15日，礼来(LLY.US)宣布，其IL-23p19单抗mirikizumab(Omvoh)已获FDA批准第2项适应症，用于治疗成人中度至重度活动性克罗恩病。Mirikizumab继2023年10月被批准为治疗中度至重度活动性成人溃疡性结肠炎(UC)的同类首创疗法之后，现在又被批准用于治疗两种类型的炎症性肠病(IBD)。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/16211547534225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IBD","BK4585","SGXZ31699556.SGD","LU2063271972.USD","IE0002141913.USD","LU1035775433.USD","LU0122379950.USD","LU0320765059.SGD","LU2237438978.USD","LU0094547139.USD","LU0106261372.USD","LU0823416689.USD","LU1983299246.USD","SG9999001176.SGD","LU1988902786.USD","LU2361045086.USD","LU1712237335.SGD","LU2112291526.USD","LU0079474960.USD","LU1061106388.HKD","LU0820561909.HKD","GB00BDT5M118.USD","LU2023250504.SGD","LU2237443978.SGD","LU2461242641.AUD","LU2264538146.SGD","LU2237443465.HKD","LU1057294990.SGD","LU0203202063.USD","LU0385154629.USD","LU2491050071.SGD","LU1974910355.USD","LU2237443549.SGD","LLY","LU2491049909.HKD","IE00BK4W5L77.USD","LU0058720904.USD","SG9999001176.USD","LU1868837300.USD","IE00BFTCPJ56.SGD","LU0820561818.USD","LU0006306889.USD","LU0256863811.USD","BK4516","LU0672654240.SGD","LU0109391861.USD","LU1069344957.HKD","SGXZ99366536.SGD","IE0004445239.USD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2502882548","title":"MNC年度涨幅榜，意外的榜一","url":"https://stock-news.laohu8.com/highlight/detail?id=2502882548","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502882548?lang=zh_cn&edition=full","pubTime":"2025-01-10 14:58","pubTimestamp":1736492297,"startTime":"0","endTime":"0","summary":"都说铁打的大药企，流水的biotech。当超9成biotech跌跌不休之际，2022年全球领先的20家药企市值平均增长了5.4%。然而，到了2024年，大药企阵营也发生了分化。而股价涨幅最高的，则是仍处于转型爬坡阶段的梯瓦。整体来看，TOP20中，过去一年股价上涨与下跌企业各占一半。其中，梯瓦、礼来和吉利德是涨幅最高的三家大药企，拜耳、再生元和诺和诺德则是跌幅前三。真正的逆袭者，是以117%涨幅问鼎TOP20榜首的梯瓦。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/248993","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4116","CD","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492588601","title":"医药行业周报：艾伯维将以2亿美元收购NIMBLE 布局自免领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2492588601","media":"太平洋证券股份...","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2492588601?lang=zh_cn&edition=full","pubTime":"2024-12-17 00:00","pubTimestamp":1734364800,"startTime":"0","endTime":"0","summary":"行业要闻：近日，艾伯维宣布，将以2 亿美元现金收购Nimble，并提供一定的中期资金支持和里程碑付款，从而获得其核心资产口服肽类IL-23 受体IL-23R 抑制剂，以及覆盖多种自身免疫疾病的创新口服肽候选药物管线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217120201ab7e131c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217120201ab7e131c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002141913.USD","LU1057294990.SGD","LU2237443895.HKD","LU1291159041.SGD","BK4559","LU0949170772.SGD","LU0708994859.HKD","LU0965509283.SGD","LU1732799900.SGD","LU1989772923.USD","IE00B42XCP33.USD","IE00BGHQF631.EUR","LU0256863811.USD","LU0310800379.SGD","LU2347655156.SGD","LU0256863902.USD","LU0310799852.SGD","LU0861579265.USD","LU0965509010.AUD","LU1496350171.SGD","LU0689472784.USD","LU0417517546.SGD","LU0795875169.SGD","BK4139","IE00BFTCPJ56.SGD","LU1003077747.HKD","LU2237443622.USD","LU0128525929.USD","LU0965508806.USD","LU0820561818.USD","LU1267930490.SGD","BK4566","LU0211328371.USD","LU0661504455.SGD","LU0122379950.USD","BK4533","LU0985320562.USD","IBD","IE00BDGV0183.EUR","LU1934455277.USD","SG9999003800.SGD","LU1732800096.USD","LU2023251221.USD","IE0009355771.USD","BK4550","BK4585","LU1244550221.USD","ABBV","SG9999011175.SGD","LU0553294199.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2478151690","title":"武田掀起新一轮裁员潮！专利悬崖、管线调整之后，整合能否找到出路？","url":"https://stock-news.laohu8.com/highlight/detail?id=2478151690","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2478151690?lang=zh_cn&edition=full","pubTime":"2024-10-27 18:56","pubTimestamp":1730026591,"startTime":"0","endTime":"0","summary":"武田制药在经历今年多轮裁员后，正计划进一步缩减员工规模。业内人士分析，武田制药近期的裁员决策主要是受到专利到期所带来的市场冲击及其对财务状况的影响。对武田制药而言，当务之急是寻找并推出下一代的主力产品。尽管武田制药通过专利诉讼试图延缓Vyvanse的专利到期，但这一努力并未能有效缓解利润下降的压力。自公布重组计划以来，武田制药已经启动了一连串的裁员措施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241027190022a1eef4bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241027190022a1eef4bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4116","IBD","BK4007","CD","ADHD","IG","TAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2476251188","title":"信达生物宣布匹康奇拜单抗（IL-23p19抗体）治疗溃疡性结肠炎的II期临床研究达成主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2476251188","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2476251188?lang=zh_cn&edition=full","pubTime":"2024-10-17 08:00","pubTimestamp":1729123200,"startTime":"0","endTime":"0","summary":"我很高兴看到匹康奇拜单抗治疗中重度活动性溃疡性结肠II期临床研究中达成主要终点，受试者获得显著的诱导期临床获益，同时安全性良好。近年来，以IL-23为靶点的新一代药物因其在溃疡性结肠炎患者治疗中卓越的疗效和良好的安全性引发关注；目前，国内市场上尚无IL-23p19靶点药物获批治疗溃疡性结肠炎，本研究是第一个由国内企业自主研发的IL-23p19单抗治疗溃疡性结肠炎的临床研究。溃疡性结肠炎严重威胁身体健康并对日常生活和心理带来影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"https://wwwold.prnasia.com/story/archive/4532408_ZH32408_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4532408_ZH32408_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1583","IBD","IVBIY","01801","LU1969619763.USD","LU2488822045.USD","BK4139","BK1161","BK1589","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inspireetf.com/etf/inspire-corporate-bond-impact-etf/","stockEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":-0.0196},{"period":"3month","weight":-0.0332},{"period":"6month","weight":-0.038},{"period":"1year","weight":-0.0503},{"period":"ytd","weight":-0.0488}],"compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1735},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.1286}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.001543},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.005311},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010014},{"month":4,"riseRate":0.444444,"avgChangeRate":0.000131},{"month":5,"riseRate":0.666667,"avgChangeRate":0.004486},{"month":6,"riseRate":0.555556,"avgChangeRate":0.001884},{"month":7,"riseRate":0.666667,"avgChangeRate":0.004234},{"month":8,"riseRate":0.5,"avgChangeRate":0.001328},{"month":9,"riseRate":0.2,"avgChangeRate":-0.00985},{"month":10,"riseRate":0.3,"avgChangeRate":-0.005871},{"month":11,"riseRate":0.555556,"avgChangeRate":0.009166},{"month":12,"riseRate":0.333333,"avgChangeRate":0.000853}],"exchange":"ARCA","name":"Inspire Corporate Bond ETF","nameEN":"Inspire Corporate Bond ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inspire Corporate Bond ETF(IBD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Inspire Corporate Bond ETF(IBD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Inspire Corporate Bond ETF,IBD,Inspire Corporate Bond ETF股票,Inspire Corporate Bond ETF股票老虎,Inspire Corporate Bond ETF股票老虎国际,Inspire Corporate Bond ETF行情,Inspire Corporate Bond ETF股票行情,Inspire Corporate Bond ETF股价,Inspire Corporate Bond ETF股市,Inspire Corporate Bond ETF股票价格,Inspire Corporate Bond ETF股票交易,Inspire Corporate Bond ETF股票购买,Inspire Corporate Bond ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inspire Corporate Bond ETF(IBD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Inspire Corporate Bond ETF(IBD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}